Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, nonrandomized, phase 1b, dose-finding study of TRC105 in
combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive
patients with stage IV non-squamous NSCLC.